Vanguard Group Inc Theseus Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.12 - $4.18 $13,629 - $26,873	6,429 Added 0.81%	795,549 $3.22 Million
Q3 2023 Nov 14, 2023	BUY	$2.66 - $10.04 $153,468 - $579,257	57,695 Added 7.89%	789,120 $2.12 Million
Q2 2023 Aug 14, 2023	BUY	$7.28 - $11.82 $221,777 - $360,084	30,464 Added 4.35%	731,425 $6.82 Million
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $325,567 - $877,970	62,489 Added 9.79%	700,961 $6.22 Million
Q4 2022 Feb 10, 2023	BUY	$4.69 - $8.36 $58,761 - $104,742	12,529 Added 2.0%	638,472 $3.18 Million

Q3 2022 Nov 14, 2022	SELL	$5.7 - $8.68 $19,214 - $29,260	-3,371 Reduced 0.54%	625,943 $3.63 Million
Q2 2022 Aug 12, 2022	BUY	$5.04 - $14.05 $720,478 - $2.01 Million	142,952 Added 29.39%	629,314 $3.48 Million
Q1 2022 May 13, 2022	SELL	$8.75 - $14.51 $3,465 - $5,745	-396 Reduced 0.08%	486,362 $5.61 Million
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $4.37 Million - $9.78 Million	486,758 New	486,758 $6.17 Million

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.